CC
Casdin Capital Portfolio holdings
AUM
$1.1B
1-Year Return
24.98%
This Quarter Return
-9.57%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$121M
AUM Growth
-$2.42M
(-2%)
Cap. Flow
+$10.4M
Cap. Flow
% of AUM
8.58%
Top 10 Holdings %
Top 10 Hldgs %
67.92%
Holding
31
New
5
Increased
12
Reduced
6
Closed
6
Top Buys
| 1 |
Illumina
ILMN
|
+$3.2M |
| 2 |
CERN
Cerner Corp
CERN
|
+$3.08M |
| 3 |
Evolent Health
EVH
|
+$2.52M |
| 4 |
AMRS
Amyris Inc.
AMRS
|
+$2.5M |
| 5 |
FMI
Foundation Medicine, Inc.
FMI
|
+$2.32M |
Top Sells
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$3.97M |
| 2 |
Exact Sciences
EXAS
|
+$2.88M |
| 3 |
GHDX
Genomic Health, Inc.
GHDX
|
+$2.6M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$1.75M |
| 5 |
iShares Biotechnology ETF
IBB
|
+$1.45M |
Sector Composition
| 1 | Healthcare | 81.46% |
| 2 | Materials | 2.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
1
DELISTED
Sage Therapeutics
SAGE
| $13.3M | 10.94% |
259,500
-7,000
| -3% | -$357K |
|
|
LOXO
2
DELISTED
Loxo Oncology, Inc
LOXO
| $11.6M | 9.55% |
360,000
+69,000
| +24% | +$2.22M |
|
|
3
Agios Pharmaceuticals
AGIO
$2.12B
| $10M | 8.29% |
240,500
-41,943
| -15% | -$1.75M |
|
|
FMI
4
DELISTED
Foundation Medicine, Inc.
FMI
| $9.66M | 7.98% |
546,000
+131,000
| +32% | +$2.32M |
|
|
5
Evolent Health
EVH
$1B
| $8.21M | 6.78% |
555,000
+170,000
| +44% | +$2.52M |
|
|
BPMC
6
DELISTED
Blueprint Medicines
BPMC
| $6.86M | 5.66% |
244,500
-42,500
| -15% | -$1.19M |
|
|
ONCE
7
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $6.41M | 5.3% |
128,500
+35,000
| +37% | +$1.75M |
|
|
GNMK
8
DELISTED
GenMark Diagnostics, Inc
GNMK
| $6.24M | 5.16% |
510,000
-115,000
| -18% | -$1.41M |
|
|
BLUE
9
DELISTED
bluebird bio
BLUE
| $5.09M | 4.2% |
6,369
+1,737
| +38% | +$1.39M |
|
10
Voyager Therapeutics
VYGR
$226M
| $4.91M | 4.05% |
385,000
+108,500
| +39% | +$1.38M |
|
|
GBT
11
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.39M | 3.63% |
304,000
+64,000
| +27% | +$925K |
|
|
KITE
12
DELISTED
Kite Pharma, Inc.
KITE
| $4.22M | 3.48% |
94,000
+4,000
| +4% | +$179K |
|
|
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $3.43M | 2.83% |
265,000
+105,000
| +66% | +$1.36M |
|
|
EPZM
14
DELISTED
Epizyme, Inc
EPZM
| $3.33M | 2.75% |
275,000
-20,000
| -7% | -$242K |
|
|
15
Illumina
ILMN
$15B
| $3.2M | 2.64% |
+25,700
| New | +$3.2M |
|
16
Alnylam Pharmaceuticals
ALNY
$60.6B
| $3.18M | 2.63% |
85,000
+46,000
| +118% | +$1.72M |
|
|
CERN
17
DELISTED
Cerner Corp
CERN
| $3.08M | 2.54% |
+65,000
| New | +$3.08M |
|
|
MDRX
18
DELISTED
Veradigm Inc. Common Stock
MDRX
| $2.86M | 2.36% |
280,000
+80,000
| +40% | +$817K |
|
|
AMRS
19
DELISTED
Amyris Inc.
AMRS
| $2.5M | 2.06% |
+228,333
| New | +$2.5M |
|
|
SYRS
20
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $2.22M | 1.83% |
18,214
+13,214
| +264% | +$1.61M |
|
|
GNMX
21
DELISTED
Aevi Genomic Medicine, Inc.
GNMX
| $1.94M | 1.6% |
375,000
| – | – |
|
22
CytomX Therapeutics
CTMX
$323M
| $1.4M | 1.16% |
127,500
| – | – |
|
|
XLRN
23
DELISTED
Acceleron Pharma Inc.
XLRN
| $1.15M | 0.95% |
+45,000
| New | +$1.15M |
|
24
Editas Medicine
EDIT
$236M
| $1.06M | 0.87% |
65,000
-20,470
| -24% | -$332K |
|
25
Gilead Sciences
GILD
$139B
| $895K | 0.74% |
+12,500
| New | +$895K |
|